International Multicentric Retrospective Study on the Use of EV+P as First-line Therapy in Patients With la/mUC

International Multicentric Retrospective Study on the Use of Enfortumab Vedotin + Pembrolizumab as First-line Therapy in Patients With Locally Advanced/Metastatic Urothelial Cancer (ARON-2PLUS)

The ARON-2PLUS Study is designed as an International Multicentric Retrospective Study to collect global experiences with the use of Enfortumab vedotin plus Pembrolizumab as first-line therapy in patients with locally advanced/metastatic Urothelial Cancer.

Two supplementary optional studies are designed: one is related to CT scans evaluation for 3D reconstruction analysis; the other one is an omic analysis on FFPE tissue.

Inclusion Criteria:

• Patients aged >18years
• Histologically confirmed diagnosis of la/mUC of upper and/or lower urinary tract or histologically confirmed diagnosis of rare GU tumors.
• Histologically or radiologically confirmed metastatic disease
• Patients treated with first-line EV+P combination

Exclusion Criteria:

• Patients without histologically confirmed diagnosis of UC
• Patients without histologically or radiologically confirmed la or mUC